About Minerva Biotechnologies
Minerva Biotechnologies is a company based in Waltham (United States) founded in 1999.. Minerva Biotechnologies has raised $18.86 million across 9 funding rounds from investors including HHS. Minerva Biotechnologies offers products and services including CAR T Therapeutics and AlphaSTEM. Minerva Biotechnologies operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
- Headquarter Waltham, United States
-
Sectors
HealthcareTechnology
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Minerva Biotechnologies Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$18.86 M (USD)
in 9 rounds
-
Latest Funding Round
$4.52 M (USD), Unspecified
Nov 14, 2023
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Minerva Biotechnologies
Minerva Biotechnologies offers a comprehensive portfolio of products and services, including CAR T Therapeutics and AlphaSTEM. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets MUC1* positive solid tumors to combat cancer metastasis.
Facilitates efficient iPSC generation and cell expansion for regenerative applications.
Unlock access to complete
Unlock access to complete
Funding Insights of Minerva Biotechnologies
Minerva Biotechnologies has successfully raised a total of $18.86M across 9 strategic funding rounds. The most recent funding activity was a Unspecified round of $4.52 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Unspecified — $4.5M
-
First Round
First Round
(30 Sep 2008)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2023 | Amount | Unspecified - Minerva Biotechnologies | Valuation |
investors |
|
| Feb, 2022 | Amount | Unspecified - Minerva Biotechnologies | Valuation |
investors |
|
| Oct, 2019 | Amount | Unspecified - Minerva Biotechnologies | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Minerva Biotechnologies
Minerva Biotechnologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Minerva Biotechnologies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Minerva Biotechnologies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Minerva Biotechnologies Comparisons
Competitors of Minerva Biotechnologies
Minerva Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| domain | founded_year | HQ Location |
Developer of CAAR T cells for B cell-mediated autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Minerva Biotechnologies
Frequently Asked Questions about Minerva Biotechnologies
When was Minerva Biotechnologies founded?
Minerva Biotechnologies was founded in 1999 and raised its 1st funding round 9 years after it was founded.
Where is Minerva Biotechnologies located?
Minerva Biotechnologies is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Is Minerva Biotechnologies a funded company?
Minerva Biotechnologies is a funded company, having raised a total of $18.86M across 9 funding rounds to date. The company's 1st funding round was a Unspecified of $1.55M, raised on Sep 30, 2008.
What does Minerva Biotechnologies do?
Minerva Biotechnologies was founded in 1999 and is based in Waltham, United States. Operations center on the biotechnology sector, where cancer immunotherapies are developed to target solid tumors and prevent metastasis. Cell therapies and antibodies form the core of these efforts, aimed at advancing treatments for various cancers through innovative immunological approaches.
Who are the top competitors of Minerva Biotechnologies?
Minerva Biotechnologies's top competitors include Juno Therapeutics, Lyell Immunopharma and Immatics.
What products or services does Minerva Biotechnologies offer?
Minerva Biotechnologies offers CAR T Therapeutics and AlphaSTEM.
Who are Minerva Biotechnologies's investors?
Minerva Biotechnologies has 1 investor. Key investors include HHS.